Ziel der Arbeitsgruppe “Clinical and Experimental Immunology of the Upper Respiratory Tract“ ist die Translation allergologischer Grundlagenforschung in neue diagnostische und therapeutische Konzepte für allergische Patienten. Dazu gehören die klinische Prüfung von neuen Allergie-Vakzinen, sowie Untersuchungen zur Barrierefunktion der Nasenschleimhaut und der Regulation der allergischen Immunantwort über die Nase. Die Arbeitsgruppe partizipiert mit dem Projekt “The nasal mucosa: A critical site for induction and maintenance, but also for prevention and therapy of type I allergy.” am vom FWF geförderten SFB F018 „Molecular and Immunological Strategies for Prevention, Diagnosis and Treatment of Type I Allergies“.
Team:
ao.Univ.Prof.Dr.med. Verena Niederberger-Leppin
Priv-Doz. Dr.med. Christian Müller
Ass.-Prof.Dr.med. Josef Toth
DDr. Katharina Gangl
DDr. Julia Eckl-Dorna
Petra Mayer (MTF)
Ausgewählte Publikationen:
Cromwell, O.*, V. Niederberger, F. Horak, and H. Fiebig. 2009. Clinical experience with recombinant molecules for allergy vaccination. Curr. Top. Microbiol. (in press)
Impact factor: 5.102
Valenta R*, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I, and Vrtala S. 2009. From allergen genes to allergy vaccines. Annu. Rev. Immunol. 2010 (in press).
Impact factor: 41.059
Twardosz-Kropfmueller A, Singh MB, Niederberger V, Horak F, Kraft D, Spitzauer S, Valenta R, Swoboda, I*. Prediction of allergic patients` phenotypes with recombinant pollen marker-allergens. Allergy 2010; 65:296-303.
Impact factor: 6.204
Pree I, Reisinger J, Bohle B, Frantal S, Valenta R*, Niederberger V. A sensitive assay for the detection of IgE bound to the major birch pollen allergen, Bet v 1, in the form of immune complexes. J Immunol Methods 2009; 345:100-5.
Impact factor: 2.120
Gangl K, Reininger R, Bernhard D, Campana R, Pree I, Reisinger J, Kneidinger M, Valent P, Wei-Chen K, Vrtala S, Spitzauer S, Valenta R, Niederberger V*. Cigarette smoke facilitates allergen penetration across respiratory epithelium and may exacerbate allergic disease. Allergy 2009; 64:398-405.
Impact factor: 6.204
Niederberger V*. Allergen-specific immunotherapy. Immunol Lett 2009; 122:131-2.
Impact factor: 2.858
Purohit A, Niederberger V, Kronquvist M, Horak F, Grönneberg R, Suck R, Meyer H, Weber B, Fiebig H, Cromwell O*, van Hage M, Pauli G, Valenta R. Immunotherapy with genetically modified birch pollen Bet v 1 derivatives improves birch pollen allergy. Clin Exp Allergy 2008;38:1514-25.
Impact factor: 3.556
Niederberger V, Valenta R. Pollen Allergy. In: Recent Advances in Aerobiology, Allergy, and Immunology, Kurup VP, Vijay H, eds. Research Signpost, Kerala, India.
Mittermann I, Reininger R, Zimmermann M, Gangl K, Reisinger J, Aichberger KJ, Greisenegger EK, Niederberger V, Seipelt J, Bohle B, Kopp T, Akdis CA, Spitzauer S, Valent P, Valenta R*. The IgE-Reactive Autoantigen Hom s 2 Induces Damage of Respiratory Epithelial Cells and Keratinocytes via Induction of IFN-gamma. J Invest Dermatol 2007; 128:1451-9 .
Impact factor: 5.251
Pree I, Reisinger J, Focke M, Vrtala S, Pauli G, van Hage M, Cromwell O, Gadermaier E, Egger C, Reider N, Horak F, Valenta R, Niederberger V*. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007;179:5309-5316.
Impact factor: 6.000
Valenta R*, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007;119:826-830.
Impact factor: 9.773
Niederberger V*, Reisinger J, Valent P, Krauth MT, Pauli G, van Hage M, Cromwell O, Horak F, Valenta R. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol 2007;119:1013-1016.
Impact factor: 9.773
Niederberger V, Ring J, Rakoski J, Jager S, Spitzauer S, Valent P, Horak F, Kundi M, Valenta R*. Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int Arch Allergy Immunol 2007;142:133-144.
Impact factor: 2.131